Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A. Hurteau, Mark F. Brady, Kathleen M. Darcy, William P. McGuire, Pamela Edmonds, Michael L. Pearl, Iouri Ivanov, Krishnansu S. Tewari, Robert S. Mannel, Kristine Zanotti, Doris M. Benbrook
Research output: Contribution to journal › Article › peer-review
71Scopus
citations
Fingerprint
Dive into the research topics of 'Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study'. Together they form a unique fingerprint.